Overview & mechanism
This blend pairs BPC-157 (local repair, angiogenesis, GI protection) with TB-500 / Thymosin Beta-4 (actin regulation, cellular migration, systemic recovery). The combination is popular in research settings because the two peptides are thought to complement each other — BPC-157 acting more locally at the injury site, TB-500 acting more systemically on cell migration and vascular remodeling.
Research dose & half-life
- Half-life:
- BPC-157 ~4 h; TB-500 fragment ~2–3 h (with prolonged tissue effects)
- Research dose:
- Typical study protocol: 250–500 mcg of each component daily or every other day, subcutaneous, over 4–6 weeks. Alternative protocol: 250–500 mcg of each component 3x weekly (e.g., Mon/Wed/Fri) for maintenance or less intensive research.
- Protocol notes:
- Schedule: subcutaneous, any consistent time of day; rotate sites to avoid localized irritation. Start/stop: acute research 4–6 weeks; maintenance 3x weekly may extend 8–12 weeks with breaks. Cautions: watch for local site reactions, unusual fatigue, or dizziness; stop and reassess if these occur.
Safety & side effects
Commonly reported: injection-site redness/bruising, mild lethargy in the first days of TB-500 use, transient head-rush or lightheadedness, and occasional GI upset. Theoretical concerns: both peptides influence angiogenesis and cell migration — use extreme caution with any history of cancer. Long-term human safety data is limited. Discontinue for persistent fatigue, unexplained swelling, allergic reaction, or chest discomfort.